HealthIndustry 2 of 8
Biopharmaceuticals
98 EIC Accelerator winners have Biopharmaceuticals as their main industry, 23% of Health.
98
Companies
+0
Also active here
14
Sub-industries
44
Technologies used
0%
Exits
18%
Show signs of scaling
Sub-industries
Technologies
- Medicinal chemistry19
- Protein engineering10
- Artificial intelligence7
- Peptide engineering6
- Vaccine technology6
- Viral vectors6
- Bioinformatics5
- Drug formulation5
- Immunotherapy5
- Monoclonal antibodies5
- Cell engineering4
- Drug delivery systems4
- Gene editing4
- Bioprocessing3
- Hydrogels3
- Microbial fermentation3
- Nanoparticles3
- Antibody-drug conjugates2
- Bacteriophages2
- Cell encapsulation2
- Molecular simulation2
- Oligonucleotides2
- Synthetic biology2
- Animal models1
Companies per year of first award
2019
2020
2021
2022
2023
2024
- Biopharmaceuticals
Show the numbers
| Companies | Biopharmaceuticals | |
|---|---|---|
| 2019 | 14 | 14 |
| 2020 | 14 | 14 |
| 2021 | 14 | 14 |
| 2022 | 23 | 23 |
| 2023 | 23 | 23 |
| 2024 | 10 | 10 |
What happened to them (98 of 98 checked)
- Active79 (81%)
- Exit0 (0%)
- Failed13 (13%)
- Other6 (6%)
Signs of scaling
- Scaling18 (18%)
- Not scaling28 (29%)
- Scaling unclear52 (53%)
Countries
Keywords
- Acinetobacter baumannii
- Alzheimer's disease
- Antimicrobial resistance
- Antivirals
- Autoimmune disease
- Bacterial infections
- Blood-brain barrier
- Brain cancer
- Cancer vaccines
- CAR-T
- Coeliac disease
- Colorectal cancer
- COPD
- COVID-19
- Crohn's disease
- Diabetes
- Diabetic foot ulcers
- Drug repurposing
- Endogenous retroviruses
- Epilepsy
- Glaucoma
- Glioblastoma
- Gut microbiome
- Haematology
- Head and neck cancer
- Immuno-oncology
- Inflammation
- Live biotherapeutics
- Neurodegeneration
- Neuropathic pain
- Neurotrophic factors
- Oncology
- Opioid alternatives
- Ovarian cancer
- Pain
- Pancreatic cancer
- Parkinson's disease
- Postoperative pain
- Rare diseases
- Solid tumours
All 98 companies in Biopharmaceuticals
| Company | Project | Country | Cut-off | Funding | Status | Rasph |
|---|---|---|---|---|---|---|
| APMONIA THERAPEUTICS | ACT-MATRIXNovel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineering | France | March 2024 | Blended finance | Active | Deep dive |
| Atamyo Therapeutics | ATA-100Smart, organotropic gene therapy designed for optimised efficacy, patient safety and affordability to treat limb-girdle muscular dystrophy-R9 | France | March 2024 | Blended finance | Active | Deep dive |
| Bio-Sourcing | BioMilk-mAbThe scale-up of the BioMilk platform: The revolutionary approach to manufacturing of biopharmaceuticals | Belgium | March 2024 | Blended finance | Active | Deep dive |
| DIAMANTE SOCIETA BENEFIT S.R.L | DIAMANTERevolutionizing Autoimmune Therapy: Antigen Specific Immunotherapy for Rheumatoid Arthritis with Virus Nanoparticles | Italy | March 2024 | Blended finance | Active | Deep dive |
| GENERA ISTRAZIVANJA DRUSTVO S OGRANICENOM ODGOVORNOSCU ZA PROIZVODNJU BIOTEHNOLOSKIH PROIZVODA | OSTEOforUNIONDrug solution for bone fracture nonunions | Croatia | March 2024 | Blended finance | Active | Deep dive |
| Impact Biotech Ltd. | IMPACTImmune Photo-Activated Cancer Therapy for the Treatment of Upper Tract Urothelial Cancer (UTUC) and other solid tumours | Israel | March 2024 | Blended finance | Active | Deep dive |
| INTEGRA THERAPEUTICS S.L. | FiCATNext generation gene writing platform to cure genetic and oncological diseases | Spain | March 2024 | Blended finance | Active | Deep dive |
| MediWound Ltd. | ESXDFUREVOLUTIONIZING DFU TREATMENT: ESCHAREX - A GAME-CHANGING SOLUTION | Israel | March 2024 | Blended finance | Active | Deep dive |
| PharmNovo AB | PN6047-DOBRAPN6047 - a breakthrough treatment of neuropathic pain | Sweden | March 2024 | Blended finance | Active | Deep dive |
| VAXDYN SL | K-VAXClinical validation of an antibiotic-resistant bacteria global vaccine platform through the first vaccine against Klebsiella pneumoniae | Spain | March 2024 | Blended finance | Active | Deep dive |
| AptaTargets, S.L. | ApTOLLApTOLL: An innovative neuroprotectant to reduce brain damage in Acute Ischemic Stroke (AIS) | Spain | November 2023 | Grant first | Active | Deep dive |
| NECTIN THERAPEUTICS | NTX1088First-in-class anti-PVR mAb NTX1088 - a novel oncology drug that unlocks the power of human immune system and revolutionizes cancer care | Israel | November 2023 | Grant first | Active | Deep dive |
| ErVaccine Technologies | OVACellDevelopment of a cell immunotherapy targeting non-conventional tumor antigens in ovarian cancer | France | June 2023 | Blended finance | Active | Deep dive |
| HEPHAISTOS-PHARMA | IVI-BoostIntraVenous Immune Boost | France | June 2023 | Blended finance | Active | Deep dive |
| PEPTINOV SAS | Anti-IL-6A breakthrough active immunotherapy for the treatment of osteoarthritis | France | June 2023 | Blended finance | Active | Deep dive |
| RESOTHER PHARMA APS | CardioProtectMIA new cardioprotective drug for acute treatment of myocardial infarction | Denmark | June 2023 | Grant first | Active | Deep dive |
| REST THERAPEUTICS | FENM4PTSDDevelopment of a novel class of therapeutics for PTSD treatment and other neurodegenerative disorders | France | June 2023 | Grant first | Active | Deep dive |
| SEA4US - BIOTECNOLOGIA E RECURSOS MARINHOS, S.A. | Sea4MarketClinical validation of a novel non-opioid analgesic derived from the Portuguese sea for treating chronic pain | Portugal | June 2023 | Blended finance | Active | Deep dive |
| SolasCure Limited | Aurase Wound GelLeveraging biomimicry and evidence-based medicine to treat patients with chronic wounds | United Kingdom | June 2023 | Grant only | Active | Deep dive |
| TAFALGIE THERAPEUTICS | TAFALGIEThe first in-class non-opioid drug for treating moderate, severe, and persistent pain with no addiction nor tolerance | France | June 2023 | Blended finance | Active | Deep dive |
| TARGTEX SA | nPL4GBMClinical validation of NANO-PL: a hydrogel-based formulation of a small molecule for a highly targeted therapy against Glioblastoma Multiforme (GBM) | Portugal | June 2023 | Blended finance | Active | Deep dive |
| Celtic Biotech Ltd | CB24Development of a natural therapeutic treatment for late-stage lung cancer patients | Ireland | March 2023 | Grant first | Active | Deep dive |
| Convert Pharmaceuticals S.A. | TUMAGNOSTICA disruptive hypoxia activated prodrug for the treatment of resistant cancers: an AI-driven approach | Belgium | March 2023 | Blended finance | Active | Deep dive |
| DiogenX SAS | DiogenXBeta-cell recovery to counter diabetes | France | March 2023 | Blended finance | Active | Deep dive |
| GeneCode AS | KevadBioDeveloping a novel Parkinson's disease drug using small molecule mimetics of Glial cell line-Derived Neurotrophic Factor (GDNF) | Estonia | March 2023 | Grant first | Active | Deep dive |
| Genewity B.V. | i-THYMUSThe i-Thymus: wielding the potential of gene therapy, cell therapy and induced pluripotent stem cells for the regeneration of the thymus and the adaptive immune system | Netherlands | March 2023 | Grant first | Active | Deep dive |
| NEOGAP Therapeutics AB | NEOpTTLInnovative approach to an Individualised T-Cell Immunotherapy for cancer, using Personalised Tumour Trained Lymphocytes (pTTL) that is reliable, cost-effective, scalable and easy to implement | Sweden | March 2023 | Blended finance | Active | Deep dive |
| Oils4cure S.L. | oils4cureOils4cure: finding an effective drug to alleviate Refractory Epilepsy, one of the most severe symptoms in the pathology of Tuberous Sclerosis | Spain | March 2023 | Grant first | Active | Deep dive |
| Panntherapi | PANNEXINPannexin 1 – a novel target for pediatric orphan epilepsy | France | March 2023 | Grant first | Active | Deep dive |
| MEDICSENSORS SL | SONOPHORESIS SMARTPATCHSonophoresis smartpatch for pain-free, controllable, and wearable transdermal drug delivery | Spain | January 2023 | Grant first | Active | Deep dive |
| Nemysis Limited | Endoprotease 40 (E40)First ever preventive treatment for celiac disease and gluten sensitivity | Ireland | January 2023 | Grant first | Active | Deep dive |
| SentryX B.V. | OPERASOpioid-free Pain relief for Enhanced Recovery After Spine fixation surgery | Netherlands | January 2023 | Blended finance | Active | Deep dive |
| SMART IMMUNE | Smart ProTcellSmart Immune ProTcell: first-in-class allogeneic thymus empowered T cell therapy platform for fast and durable immune system reconstitution | France | January 2023 | Blended finance | Insolvent | Deep dive |
| Arctic Therapeutics ehf | DNACADementia/Alzheimer Drug Attributed to Cystatin-C and other mutations – precision medicine drug development | Iceland | October 2022 | Blended finance | Active | Deep dive |
| Gate2brain S.L. | GATE2BRAINGATE2BRAIN. Medicines beyond barriers. | Spain | October 2022 | Grant first | Active | Deep dive |
| HERANTIS PHARMA OYJ | ReTreatPDRevolutionary therapeutic treatment for stopping progression of Parkinson's disease | Finland | October 2022 | Blended finance | Active | Deep dive |
| iOnctura BV | CURE-PDACCURE-PDAC | Netherlands | October 2022 | Blended finance | Active | Deep dive |
| My Personal Therapeutics Limited | AI-PDPApplying AI to scale up the Personal Discovery Process-A world-first, full-genome, personalised patient clinical trial for cancer | United Kingdom | October 2022 | Grant only | Active | Deep dive |
| Protinhi B.V. | ATLASThe first broad-spectrum treatment against pandemic-prone flaviviral infections: Dengue, West-Nile and Zika | Netherlands | October 2022 | Blended finance | Insolvent | Deep dive |
| XENIKOS BV | MIT-IDModulatory immunotherapy for severe immune disease | Netherlands | October 2022 | Grant first | Closed | Deep dive |
| Antabio SAS | sbli-ant3310A novel combination treatment effective against all multidrug-resistant pathogens deemed as a critical priority by the WHO | France | June 2022 | Blended finance | Active | Deep dive |
| ARTHEx Biotech S.L. | fight-dm1First In class oliGo THerapy for Myotonic Dystrophy type 1 (DM1) | Spain | June 2022 | Blended finance | Active | Deep dive |
| ATXA Therapeutics Ltd | PAH-AdvancePAH-ADVANCE: Accelerating the Clinical Path of NTP42, a disease-modifying drug that will disrupt the future treatment of cardiopulmonary diseases, including pulmonary arterial hypertension (PAH). | Ireland | June 2022 | Blended finance | Active | Deep dive |
| Celeris Therapeutics GmbH | CelerisTx - Celeris One PlatformClosed-loop deep learning in early-stage drug discovery - cloud platform for targeted protein degradation | Austria | June 2022 | Blended finance | Insolvent | Deep dive |
| ELGAN Pharma Ltd. | ELGN-GIA first-in-class therapy for intestinal malabsorption in premature newborns | Israel | June 2022 | Grant first | Active | Deep dive |
| Hemispherian AS | CureGLIOClinical validation of GLIX1: a small molecule that targets epigenetic changes in cancer cells to treat glioblastoma multiforme (GBM), the highest global unmet need in oncology. | Norway | June 2022 | Blended finance | Active | Deep dive |
| Immunethep S.A. | PARAGON NOVEL VACCINEParagon Novel Vaccine (PNV) an effective protection against all serotypes of five deadly bacteria to eradicate Antimicrobial Resistance (AMR) | Portugal | June 2022 | Grant first | Active | Deep dive |
| Meletios Therapeutics | FLUIDITYFighting Large-Scale Untreated Infectious Diseases with Innovative Treatments | France | June 2022 | Blended finance | Insolvent | Deep dive |
| ALKION BIOINNOVATIONS | AlkaBurst2.0AlkaBurst2.0 – A game changing bioreactor for sustainable production of active pharmaceutical ingredients in a consistent, traceable and low cost approach | France | March 2022 | Blended finance | Active | Deep dive |
| Aplagon Oy | APAC-ONAPAC – the first targeted therapy for peripheral arterial occlusive disease. | Finland | March 2022 | Blended finance | Active | Deep dive |
| Brainever | HOMEOBRAINHomeoproteins as novel therapies for neurodegenerative diseases | France | March 2022 | Grant first | Active | Deep dive |
| Camino Science sp. z o.o. | in silico bio-evolutioin silico bio-evolutio - novel AI paradigm for molecular biology | Poland | March 2022 | Grant first | Active | Deep dive |
| Elicera Therapeutics AB | CD20CARNAPTiTANK: a nuniversal technology to boost the efficacy of CAR T cell therapies by inducing dual mode-of-actio | Sweden | March 2022 | Grant only | Active | Deep dive |
| Nemesis Bioscience Ltd | TransmidsInactivation of antimicrobial resistance (AMR) genes in an animal gut microbiome and prevention of horizontal AMR gene transmission | United Kingdom | March 2022 | Grant only | Closed | Deep dive |
| PERHA PHARMACEUTICALS SAS | DOWN-AUTONOMYLCTB-21: A DYRK1A protein kinase inhibitor for treatment of cognitive decline in Down Syndrome. | France | March 2022 | Blended finance | Active | Deep dive |
| TILT BIOTHERAPEUTICS OY | I-CREATEFighting cancer with next generation oncolytic immunotherapy in ovarian, head & neck, and lung cancers (Immune Checkpoint Response Enabling Adenovirus Technology ) | Finland | March 2022, March 2024 | Blended finance | Active | Deep dive |
| Allero Therapeutics BV | SOMIT-CDNovel First-in-Class Specific Oromucosal Immunotherapy (SOMIT) to treat Celiac Disease (CD) | Netherlands | October 2021 | Grant first | Active | Deep dive |
| Edvince AB | EDVanceEDV2209 – a Paradigm shift in the treatment of stroke. | Sweden | October 2021 | Grant first | Active | Deep dive |
| Fibriant B.V | RECOFIBA unique commercially viable recombinant manufacturing platform for human fibrinogen (rhFib) & thrombin (rhThr | Netherlands | October 2021 | Blended finance | Active | Deep dive |
| LiMM Therapeutics SA | PILCKYHarnessing the therapeutic Potential of Innate Lymphoid Cells to prevent and treat KidneY-related diseases | France | October 2021 | Blended finance | Closed | Deep dive |
| NETRIS PHARMA SAS | ImmunoNetInhibiting resistance to immunotherapy in Oncology by targeting Netrin-1 | France | October 2021 | Blended finance | Active | Deep dive |
| Op2Lysis | OP2DRAINTo deliver the first medical treatment dedicated to patients with haemorrhagic stroke | France | October 2021 | Blended finance | Insolvent | Deep dive |
| PALOBIOFARMA, S.L | RESPIREDevelopment of the first oral disease-modifying treatment for chronic obstructive pulmonary disease (COPD) | Spain | October 2021 | Blended finance | Active | Deep dive |
| Vascular Biogenics LTD | OVALThe OVAL study for VB-111 treatment of platinum-resistant ovarian cancer | Israel | October 2021 | Blended finance | Insolvent | Deep dive |
| EVerZom SAS | ACROBATToward democratisation of extracellular vesicles-based therapies | France | June 2021 | Grant first | Active | Deep dive |
| Hoba Therapeutics ApS | Sense21HB-086 and HB-097 for treatment of chronic sensory neuronal disorders - neuropathic pain and hearing loss | Denmark | June 2021 | Grant first | Active | Deep dive |
| InProTher ApS | CancERVaccTargeting Cancer with ERV Vaccines | Denmark | June 2021 | Blended finance | Active | Deep dive |
| PROSION GmbH | ProMThe ProM platform: New ways to drug the undruggable | Germany | June 2021 | Grant first | Insolvent | Deep dive |
| Qubit Pharmaceuticals SAS | ATLASNext generation HPC/QC in silico drug discovery platform leveraging the latest advances in high-performance and quantum computing | France | June 2021 | Blended finance | Active | Deep dive |
| VarmX BV | StopBleedingThe first effective and safe reversal agent to stop or prevent life-threatening bleeding in patients taking the emerging generation of anticoagulants. | Netherlands | June 2021, October 2024 | Blended finance | Active | Deep dive |
| Omnix Medical Ltd | OMN6A novel class of antibiotics to combat Antimicrobial Resistance | Israel | October 2020 | Blended finance | Active | Deep dive |
| BETALIN THERAPEUTICS LTD | Micro PancreasCure Diabetes by Injection of Micro Pancreas Cell Therapy | Israel | March 2020 | Grant only | Active | Deep dive |
| EXELIOM BIOSCIENCES | EXL01The game changing drug in Crohn’s Disease : a unique standard of care for a healthy long-term remission | France | March 2020 | Grant only | Pivoted | Deep dive |
| Exvastat Ltd | ImpentriFirst effective pharmacotherapy for ARDS to lower mortality and improve quality of life of patients. | Ireland | March 2020 | Grant only | Closed | Deep dive |
| Faron Pharmaceuticals Oy | MAGIFFaron leading the way in macrophage guided immunotherapy | Finland | March 2020 | Grant only | Active | Deep dive |
| Ilya Pharma AB (publ) | WHILYAS-2Wound healing ILYA-style 2 | Sweden | March 2020 | Grant only | Active | Deep dive |
| OSIVAX SAS | OSIRIXRevolutionary vaccines to prevent pandemic and seasonal outbreaks of respiratory viral infections: The best-in-class UNIVERSAL multi-season influenza vaccine | France | March 2020 | Blended finance | Active | Deep dive |
| Remedy Biologics Limited | RapCo-19Rapid COVID-19 Passive Therapy Response Platform | Ireland | March 2020 | Blended finance | Active | Deep dive |
| XENOTHERA | BRIGHTTreat severe cases of infection at COV with XAV-19 | France | March 2020 | Grant only | Pivoted | Deep dive |
| Ability Pharmaceuticals SA | PanC-ASAPAbilityPharma: Accelerating Solutions for Pancreatic Cancer | Spain | January 2020 | Blended finance | Active | Deep dive |
| FluoGuide A/S | INSTAGLOWGame-changing uPAR-targeting dye for guiding surgical treatment of cancer | Denmark | January 2020 | Grant only | Active | Deep dive |
| Hamlet BioPharma AB | HAMLET-BCAlpha1H: A Unique Bladder Cancer Therapeutic, Acting with Great Precision | Sweden | January 2020 | Grant only | Active | Deep dive |
| PHARMACELERA SL | PharmScreen2Holistic Quantum Mechanics Based Platform to Accelerate Drug Discovery | Spain | January 2020 | Grant only | Active | Deep dive |
| SIGNIA THERAPEUTICS SAS | SigniaAn innovative drug development and repurposing platform for rapid identification and validation of antimicrobial therapeutics | France | January 2020 | Grant only | Closed | Deep dive |
| Biodexa Ltd | GlioKIDSDevelopment of MTX110 as a Convection Enhanced Delivery (CED) treatment for Diffuse Intrinsic Pontine Glioma (DIPG) in children | United Kingdom | October 2019 | Blended finance | Pivoted | Deep dive |
| EpiEndo Pharmaceuticals hf. | BRONCHOTHELINThe first-in-class disease-modifying drug for chronic airway disorders | Iceland | October 2019 | Blended finance | Active | Deep dive |
| MYBIOTICS PHARMA LTD | MBSelectA novel technology enabling efficient delivery of personalized probiotics to prevent gut-related diseases and recover damaged gut microbiota | Israel | October 2019 | Blended finance | Unknown | Deep dive |
| InterAx Biotech AG | PICARDDISRUPTIVE GPCR LEAD DISCOVERY PLATFORM DELIVERING NEW AND SAFER THERAPEUTICS | Switzerland | June 2019 | Grant only | Active | Deep dive |
| MaxiVAX SA | MaxONCOA cancer vaccine to boost body’s natural defences to fight chordoma and head and neck cancer | Switzerland | June 2019 | Grant only | Pivoted | Deep dive |
| RHOVAC ApS | RV001RV001: An anti-metastatic cancer vaccine | Denmark | June 2019 | Grant only | Pivoted | Deep dive |
| Tarsier Pharma Ltd | TRSA paradigm change in the treatment of blinding ocular diseases | Israel | June 2019 | Grant only | Active | Deep dive |
| TreeFrog Therapeutics SAS | C-stemGMPc-GMP compliance of C-stem, an IPSc based cell therapies production technology | France | June 2019, October 2024 | Grant only | Active | Deep dive |
| KINNOV THERAPEUTICS | StopAddictThe game changer drug to cure alcohol use disorders | France | April 2019 | Grant only | Active | Deep dive |
| Micreos Human Health B.V. | StaphIMPACTSA.100: Next-generation targeted antibacterial product entering European market | Netherlands | April 2019 | Grant only | Active | Deep dive |
| PEPTOMYC SL | MYCureInnovative cancer therapy through Myc inhibition: taking OMO-103 to market | Spain | April 2019, June 2023 | Grant only | Active | Deep dive |
| SparingVision SAS | SIROCOSparing gene therapy for Inherited ROd COne dystrophies | France | April 2019 | Grant only | Active | Deep dive |
| Eligo Bioscience SA | SPELITECSequence sPecific ELImination of shiga-Toxin E. Coli | France | January 2019 | Grant only | Active | Deep dive |
| Elthera AG | Anti-L1CAMAnti-L1CAM antibody: A novel efficacious immunotherapy for pancreatic and ovarian cancer patients | Switzerland | January 2019 | Grant only | Dormant | Deep dive |
Other industries in Health: Medical devices · In vitro diagnostics · Life science tools · Digital health · Animal health · Public health products · Pharmacy technology